Challenges and Solutions in Lipid-Lowering Therapy in Women: From Gaps to Practice-Changing Advances
Atherosclerotic cardiovascular disease (ASCVD) events are among the leading causes of death in women in the US and globally.
Category
  • CMHC
Format
  • Self-study / Enduring
Credits
  • 1.50 ACPE Pharmacy
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC
  • 1.50 Participation
Cost $0.00
Escape Room Experience: Individualizing Treatment for Patients with Chronic Kidney Disease and Type 2 Diabetes
The coexistence of type 2 diabetes and chronic kidney disease significantly exacerbates cardiovascular and renal morbidity and mortality compared to either condition alone. Even with the advent of newer therapies in patients with T2D and CKD, such as sodium-glucose cotransporter-2 (SGLT-2) inhibi
Category
  • CMHC
Format
  • Self-study / Enduring
Credits
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
Cost $0.00
Breaking Through Inertia: How to Initiate and Maintain Insulin Therapy in Patients with Type 2 Diabetes
This interactive infographic covers a variety of topics surrounding the role of insulin therapy in type 2 diabetes (T2D) management, including practical pearls for initiation and maintenance of insulin therapy, how insulin therapy fits in with other T2D treatment options, a
Category
  • CMHC
Format
  • Self-study / Enduring
Credits
  • 1.50 AAFP
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Participation
Cost $0.00
The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects an estimated 25-30% of people in the United States and can often progress to Metabolic dysfunction-associated steatohepatitis (MASH) and cirrhosis.
Category
  • CMHC
  • TME
Format
  • Self-study / Enduring
Credits
  • 0.75 ACPE Pharmacy
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC
  • 0.75 Participation
Cost $0.00
Exploring Novel Strategies for LDL-C Combination Therapy to Decrease ASCVD Risk: A Paradigm Shift
Effectively and safely lowering LDL-C is essential to prevent and reduce the risk of recurrent ASCVD events.
Category
  • CMHC
Format
  • Self-study / Enduring
Credits
  • 1.50 ACPE Pharmacy
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC
  • 1.50 CDE
  • 1.50 Participation
Cost $0.00
Understanding the Role of Lp(a) as a CV Risk Marker to Therapeutic Target in the Prevention of ASCVD
Residual ASCVD risk may be present even after the optimization of LDL-C levels and increasing evidence has suggested that elevated Lp(a) is an emerging CVD risk factor that has been shown to be a causal CVD risk factor in epidemiological and genetic studies, as well as enha
Category
  • CMHC
Format
  • Self-study / Enduring
Credits
  • 1.50 ACPE Pharmacy
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC
  • 1.50 CDE
  • 1.50 Participation
Cost $0.00
Ace the Case Challenge Series: Exploring Novel Strategies for LDL-C Combination Therapy to Decrease ASCVD Risk
Effectively managing high cholesterol level and safely lowering LDL-C is crucial for preventing and reducing the risk of adverse cardiovascular events. However, achieving LDL-C goals remains suboptimal, particularly in high-risk and very high-risk patients.
Category
  • CMHC
Format
  • Self-study / Enduring
Credits
  • 0.75 ACPE Pharmacy
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC
  • 0.75 Participation
Cost $0.00
Ace the Case Challenge Series: The Intersection of MASH and Cardiometabolic Risk
This Ace the Case Series is designed to be quick and offer high-level takeaways and pearls.Case #1:  A 37-Year-Old Man with Incidental Hepatic Steatosis on Abdominal Ultrasound
Category
  • CMHC
Format
  • Self-study / Enduring
Credits
  • 0.50 ACPE Pharmacy
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC
  • 0.50 CDE
  • 0.50 Participation
Cost $0.00
The Burden of Resistant Hypertension in Women: Novel and Emerging Approaches to Improve Outcomes
This activity consists of a recorded presentation at the 2024 Women's Health and Wellness Masterclass, held in April 2024 in Dana Point, CA.  The session, "The Burden of Resistant Hypertension in Women: Novel and Emerging Approaches to Improve Outcomes" was presented by Debbie Cohen, MD
Category
  • CMHC
Format
  • Self-study / Enduring
Credits
  • 0.50 ACPE Pharmacy
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC
  • 0.50 Participation
Cost $0.00
The Risk Stratification and Treatment of Chronic Kidney Disease in Women: Uncovering and Addressing Disparities to Improve Outcomes
This activity consists of a recorded presentation at the 2024 Women's Health and Wellness Masterclass, held in April 2024 in Dana Point, CA.  The symposium, "The Risk Stratification and Treatment of Chronic Kidney Disease in Women: Uncovering and Addressing Disparities to Improve Outcomes" was pr
Category
  • CMHC
Format
  • Self-study / Enduring
Credits
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
Cost $0.00

Pages